$5.24
+1.75%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.09
From 52W high−55.06%
Volume82137.00
Market cap$76.20M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$5.09
From 52W high
−55.06%
Volume
82137.00
Market cap
$76.20M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
49.5
MomentumView details →
1D Return
+1.75%
YTD Return
+18.66%
SummaryUpdated Jun 1, 2026
Cingulate Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Kansas City, Kansas. The company went public in December 2021 and focuses on developing innovative treatments for neurological and psychiatric disorders. Cingulate is currently advancing multiple drug candidates through clinical trials, with its primary focus on attention-deficit/hyperactivity disorder (ADHD) treatments and anxiety disorders.
Similar companies
Latest newsMore news →
Cingulate Inc. reported its financial results for the second quarter ended June 30, 2026.38d agoCingulate Inc. appointed Zhanpeng "Frederick" Jiang as chairman of the Audit Committee of the Board of Directors, effective July 9, 2026.69d agoCingulate Inc. promoted Shane J. Schaffer to Chief Executive Officer and chairman of the Board of Directors, effective July 9, 2026.69d ago